Health Economics›Acute myeloid leukemia›Relapsed or refractory further lines of therapy

Relapsed or refractory further lines of therapy

Acute myeloid leukemia · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine and Sorafenib Variant #01	FLT3	R 61 372	56d	—	—	—	—	—
FLAG-Ida Variant #01	FLT3	R 35 219	28d	—	5.4 mo	—	—	3
MEC Variant #01	FLT3	R 19 351	28d	—	5.4 mo	—	—	3
Azacitidine monotherapy Variant #01	FLT3	R 18 699	28d	—	~8.7 mo	—	—	11
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	FLT3	R 172	28d	—	4.7 mo	—	—	1
Gilteritinib monotherapy Variant #01 Partial	FLT3	—	28d	—	9.6 mo	—	—	1
Quizartinib monotherapy Variant #01 Partial	FLT3	—	28d	—	~6.2 mo	—	—	1

7 of 7 regimens shown